Veracyte director sells 5,000 shares at $40.95

Veracyte director Jens Holstein sold 5,000 shares under a Rule 10b5-1 plan and now directly holds 27,471 shares.

Rhea-AI Filing Summary

VERACYTE, INC. (VCYT) director Jens Holstein reported selling 5,000 shares of common stock on September 14, 2026 in a transaction coded as a sale in open market or private transactions. The shares were sold at a weighted average price of $40.95 per share and Holstein now holds 27,471 shares directly.

The sale was made pursuant to a Rule 10b5-1 plan adopted on June 12, 2026, and the filing states that individual sale prices during the transaction ranged from $40.57 to $41.40 per share.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Holstein Jens

Role Director

Sold 5,000 shs ($205K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	5,000	$40.9494	$205K

Holdings After Transaction: Common Stock — 27,471 shares (Direct)

Footnotes (2)

1. F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2026.
2. F2. Represents weighted average sales price. Sale prices for the transactions range from $40.57 to $41.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $40.95 per share Sale price range: $40.57–$41.40 per share +3 more

6 metrics

Shares sold 5,000 shares Non-derivative sale of Veracyte common stock on September 14, 2026

Weighted average sale price $40.95 per share Average price for 5,000 shares sold by Jens Holstein

Sale price range $40.57–$41.40 per share Range of individual sale prices within the reported transaction

Shares held after transaction 27,471 shares Direct ownership reported for Jens Holstein following the sale

Rule 10b5-1 plan adoption date June 12, 2026 Date Holstein adopted the trading plan used for these sales

Net shares sold in filing 5,000 shares Net sell direction across all reported transactions in this Form 4

Key Terms

Rule 10b5-1 plan, weighted average sales price, non-derivative, open market or private transaction

4 terms

Rule 10b5-1 plan regulatory

"transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"Represents weighted average sales price. Sale prices for the transactions range"

non-derivative financial

"transaction_type": "non-derivative""

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veracyte (VCYT) director Jens Holstein report?

Jens Holstein reported a sale of 5,000 Veracyte common shares on September 14, 2026, in a transaction coded as a sale in open market or private transactions, at a weighted average price of $40.95 per share.

How many Veracyte (VCYT) shares does Jens Holstein hold after this Form 4 trade?

After the reported transaction, Jens Holstein directly holds 27,471 shares of Veracyte common stock. This figure reflects his post-transaction ownership reported on the Form 4 filed for the September 14, 2026 sale.

Was the Veracyte (VCYT) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 plan adopted by Jens Holstein on June 12, 2026, indicating the sales followed a pre-established trading plan.

What price did Jens Holstein receive for the sold Veracyte (VCYT) shares?

The sale had a weighted average price of $40.95 per share. A footnote explains that individual sale prices for the 5,000 shares ranged from $40.57 to $41.40, with detailed price breakdowns available upon request.

How many Veracyte (VCYT) shares did Jens Holstein sell in this Form 4?

Jens Holstein sold 5,000 shares of Veracyte common stock in this reported transaction, which is categorized as a non-derivative sale of common stock on September 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:08 PM Accepted by SEC EDGAR 09/16/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holstein Jens

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S(1)		5,000	D	$40.9494(2)	27,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2026.

2. Represents weighted average sales price. Sale prices for the transactions range from $40.57 to $41.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)